IVIG at Home: What It Is, Who It Helps, and Why the Details Are the Safety Story
A nurse's guide for patients, pharmacies, and referral partners
Our nurses have spent their careers around infusions, first at the bedside in the ICU and then in patients' homes. In that time we have watched IVIG go from something most people had never heard of to one of the most commonly referred specialty therapies in home infusion.
We have also watched a lot of confusion follow it around. Patients get a prescription, a pharmacy phone number, and a promise that a nurse will be out on Tuesday. Referral sources send patients our way without always knowing what the therapy involves. Nurses new to specialty infusion sometimes treat it like any other piggyback.
It is not like any other piggyback. Here is what IVIG is, who it is for, what actually happens during an infusion, and why the small operational details are the entire safety story.
What IVIG actually is
IVIG stands for intravenous immunoglobulin. It is a plasma derived biologic: it comes from human donors, not a chemistry lab. The active ingredient is immunoglobulin G (IgG), the antibody your immune system uses to recognize and neutralize threats it has seen before.
Here is the part that surprises most people. A single batch is made from pooled plasma collected from thousands of healthy donors. That pooling is the point. Every donor brings a lifetime library of antibodies, and pooling them produces a far broader range than any one person could build alone. Donors and plasma are screened, and manufacturing includes dedicated viral inactivation and removal steps.
When a patient receives IVIG, they are not receiving a drug in the traditional sense. They are receiving a concentrated, purified, standardized piece of collective human immunity.
One bag, two very different jobs
IVIG is used for two purposes that look almost opposite to each other.
The problem: Replacement: The body does not make enough functional antibody / Immunomodulation: The immune system attacks the wrong target
Classic example: Replacement: Primary immunodeficiency (PI) / Immunomodulation: CIDP, ITP, other autoimmune conditions
Typical dose: Replacement: About 300 to 600 mg/kg every 3 to 4 weeks / Immunomodulation: About 1 to 2 g/kg per course
Titrated to: Replacement: IgG trough levels and, more importantly, how often the patient gets sick / Immunomodulation: Clinical response
PI patients often spend years cycling through sinus, lung, and ear infections and round after round of antibiotics before anyone connects the pattern. For them, IVIG replaces something their body is missing. For autoimmune patients, the much higher dose acts on the immune system itself. The mechanisms are still being worked out, but the clinical effect is well established.
Same product. Same bag. Completely different dose, rationale, and monitoring.
Who gets IVIG
FDA labeled indications vary by brand, and no single product carries every one. Across the products on the market, labeled uses include:
Primary humoral immunodeficiency
Chronic immune thrombocytopenia (ITP)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Multifocal motor neuropathy (MMN)
Kawasaki disease
Prevention of bacterial infection in chronic lymphocytic leukemia
A large share of real world use is off label and evidence supported: Guillain Barre syndrome, myasthenia gravis, inflammatory myopathies, stiff person syndrome, autoimmune encephalitis, certain vasculitides, autoimmune hemolytic anemia, and others. In neurology, chronic neuropathy is one of the highest volume reasons IVIG gets ordered.
Two takeaways for anyone coordinating this care. Brand matters: products are not freely interchangeable, and the label on one is not the label on another. And the indication drives the dose, which drives the risk. A CIDP patient at 2 g/kg and a PI patient at 400 mg/kg are not the same visit.
What happens during a home infusion
A typical home IVIG visit runs two to six hours, sometimes longer, and it should follow the same rhythm every time.
Before. The nurse confirms the order, product, lot, expiration, and dose against the patient's current weight. Hydration is assessed, because here hydration is a safety intervention, not a comfort measure. Baseline vitals are taken, and premedication (commonly acetaminophen and an antihistamine) is given if ordered.
During. The infusion is a rate titration, not a set it and forget it drip. Start low, often around 0.5 to 1 mg/kg/min depending on product and patient. Hold, reassess, and step up in defined increments only if the patient is tolerating it. Vitals at baseline, at every rate change, and at the end. Epinephrine and an anaphylaxis protocol on hand every visit, no exceptions.
After. The patient is observed, the line is flushed, and everything is documented: product, lot number, actual rates and times, vitals at every checkpoint, symptoms, any rate reduction, and tolerance.
Most reactions show up during a rate increase or in the first 30 to 60 minutes. That is why the titration steps matter so much.
Lot number documentation is not paperwork for its own sake. This is a plasma derived product, and traceability from donor pool to patient arm is a regulatory requirement.
The risks are real, and two of them are boxed
Every immune globulin product carries an FDA boxed warning for thrombosis. Every IVIG product also carries one for renal dysfunction and acute renal failure.
Thrombosis. IVIG can cause arterial and venous clots, including heart attack, stroke, DVT, and pulmonary embolism. Risk factors include advanced age, immobility, hypercoagulable states, prior thrombosis, estrogen use, indwelling central catheters, hyperviscosity, and cardiovascular disease. The line clinicians should not skip: clots have occurred in patients with no known risk factors at all.
Renal. Acute kidney injury and osmotic nephrosis have been linked to IVIG, historically concentrated in sucrose stabilized products. Those have since left the U.S. market, which cut the incidence materially, but the warning remains. Watch patients with existing renal insufficiency, diabetes, age over 65, volume depletion, sepsis, paraproteinemia, or concurrent nephrotoxic drugs.
The mitigation for both is one sentence, written into essentially every IVIG package insert: give the minimum dose and infusion rate practicable, and ensure adequate hydration before administration.
In the home, that sentence is executed by one nurse at a kitchen table, or it is not executed at all.
Beyond the boxed warnings, expect headache, chills, flushing, muscle aches, low grade fever, nausea, and fatigue. Most are rate related and ease when you slow down. Less common but important: aseptic meningitis (usually within a day or two, more often at high doses), hemolysis (higher risk at high doses and in non-O blood types), transfusion related acute lung injury, and true anaphylaxis, a specific concern in patients with severe IgA deficiency and anti-IgA antibodies.
One more that gets missed constantly: IVIG interferes with live virus vaccines and can confound serologic testing. Vaccine timing needs to be planned, not discovered after the fact.
IVIG or SCIG?
Immunoglobulin can also be given subcutaneously. Neither route is universally better; both deserve a conversation with every patient on immunoglobulin.
Schedule: IVIG: Larger doses every 3 to 4 weeks / SCIG: Smaller doses weekly or every other week
IgG levels: IVIG: Peaks and troughs / SCIG: Steadier, absorbed over 1 to 3 days
Thrombosis boxed warning: IVIG: Yes / SCIG: Yes
Renal boxed warning: IVIG: Yes / SCIG: No, a strong option for patients with kidney risk
Access: IVIG: Venous access needed / SCIG: No IV needed
Facilitated SCIG adds a hyaluronidase pre-infusion so larger volumes can be given at longer intervals. The right route depends on venous access, tolerance, other conditions, lifestyle, and what the patient will actually stick with.
Why home matters
For years, IVIG meant a full day in a hospital or infusion suite every three to four weeks, indefinitely. For a working adult or a parent, that is not a treatment plan. It is a second job.
Home changes that math. Patients report better quality of life, less travel and time off work, less exposure to whatever is circulating in a waiting room, and real control over their own schedule. Home is also generally the lowest cost site of care for this therapy.
Policy has caught up. Since January 1, 2024, under Section 4134 of the Consolidated Appropriations Act, 2023, Medicare Part B pays a permanent bundled amount for the items and services needed to give IVIG at home to beneficiaries with primary immunodeficiency. It replaced the decade long demonstration project and requires no special enrollment by the patient. Commercial coverage varies, and non-PI indications follow different rules, so verification is still case by case.
The honest caveat: home is not automatically right for every patient. A good home candidate is clinically stable, has a documented history of tolerating the therapy, has usable access, has emergency services within reach, and has someone present during the infusion. Moving a patient home before those conditions are met is not patient centered care. It is risk transfer.
The nurse is the safety system
This is the part we most want referral partners and pharmacies to hear.
In a hospital, there is a code team down the hall. In an infusion suite, there is a charge nurse and three other clinicians in the room. In the home, there is one nurse. That nurse is the assessment, the titration decision, the reaction recognition, the emergency response, and the documentation. There is no backup in the next room.
So the quality of a home IVIG program is not decided by logistics. It is decided by whether the nurse walking through that door:
has been trained specifically in immunoglobulin therapy, with competency validated
knows the difference between a rate related headache and the beginning of something worse
carries the anaphylaxis protocol and knows it cold
documents to a standard that will hold up in a payer audit or an accreditation survey
That is why documentation standards, competency files, and infusion protocols are not back office overhead. Under Infusion Nurses Society standards, ACHC Home Infusion Therapy standards, and CMS expectations, the clinical record is the proof the care happened correctly. If a rate change is not documented, clinically it did not happen.
How DOMO Health does it
DOMO Health is a nurse led specialty home infusion company. We are not a home health agency. Our nurses administer specialty therapies, including IVIG and SCIG, in patients' homes for the pharmacies and referral sources we partner with. Clinical quality is the only product we actually sell. On every IVIG visit that means:
Competency validated infusion nurses
A standardized pre-infusion assessment and rate titration practice
Anaphylaxis readiness, every visit
Documentation reviewed by our Director of Nursing before it goes back to the pharmacy
A policy and document control structure built against ACHC Home Infusion Therapy and INS standards as we work toward ACHC accreditation
24/7 on-call clinical support for our nurses
Let's work together
Pharmacies and referral partners. If you need IVIG or SCIG nursing coverage in North Carolina, South Carolina, Georgia, Alabama, Michigan, Arizona, Massachusetts, or Utah, send referrals to intake@domohealthgroup.com or call 704-909-1423. We confirm every referral within 20 minutes.
Infusion nurses. If you want specialty infusion work with real clinical support behind you, we are hiring W-2 PRN home infusion RNs across our states. Visit the Careers page at domohealthgroup.com or email talent@domohealthgroup.com.
Patients and families. Ask your prescriber and pharmacy whether home infusion is right for you. Questions about this article are welcome in the comments.
This is the first of an ongoing series. Not marketing, education. Follow DOMO Health for the next pieces on specialty home infusion.
DOMO Health is a nurse led specialty home infusion company based in North Carolina and serving patients across eight states.
This article is general education and is not medical advice. Treatment decisions, dosing, and site of care belong to the patient and their prescriber.
References
FDA prescribing information: Gamunex-C, Octagam 10%, Flebogamma 5% DIF, Gammaplex (boxed warnings, dosing, infusion rates)
CMS MLN Fact Sheet, Intravenous Immune Globulin Items and Services (MLN3191598)
CMS, Home Infusion Therapy and Home IVIG Services
Consolidated Appropriations Act, 2023, Section 4134
Immune Deficiency Foundation, Medicare Home IVIG Benefit
Infusion Nurses Society, Infusion Therapy Standards of Practice
ACHC Home Infusion Therapy accreditation standards
Comments